HCN Oncology Essentials: EPOCH vs. R-CHOP, Ageism & Ableism, SCLC SurvivalNovember 30, 2021 | Oncology Hematology DA-R-EPOCH vs. R-CHOP in DLBCL: How Do We Choose? DLBCL is increasingly being recognized as a heterogeneous disease with distinct molecular subtypes. This has challenged the rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) treatment paradigm in recent years, as several DLBCL subtypes have inferior survival after standard R-CHOP therapy. So how do you choose? In this review the authors conclude with proposed clinical management scenarios in which DA-R-EPOCH may be preferred, including some for patient populations in which the use of R-CHOP vs. DA-R-EPOCH is controversial. Read full article Geriatrics Who is MB and What Does She Want? “MB” is a frail, wheelchair-ridden, nearly blind, and mostly deaf woman living with early dementia and neglected lung cancer. What this oncologist thought MB wanted and needed was a lot different than what MB actually wanted and needed after discussing various options with her and talking to her family on numerous occasions. A humbling, honest view of an oncologist’s biases. Read full article
DIET & NUTRITION 
PATIENT EDUCATION 
OBESITY/WEIGHT MANAGEMENT 
EXERCISE/TRAINING 
LEGAL MATTERS 
GUIDELINES/RECOMMENDATIONS